Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028337) TREATING AND INHIBITING LEUKEMIA WITH NK-92 CELLS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028337 International Application No.: PCT/US2018/045146
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
A61K 45/06 (2006.01) ,A61K 35/17 (2015.01) ,C12N 5/00 (2006.01) ,A61P 35/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
[IPC code unknown for A61K 35/17]
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
Applicants:
NANTKWEST, INC. [US/US]; 3530 John Hopkins Court San Diego, California 92121, US
Inventors:
KLINGEMANN, Hans G.; US
LEE, Tien; US
Agent:
BORING, Landin F.; US
SERAFINI, Andrew T.; US
THOMAS, Tiffany B.; US
LOCKYER, Jean M.; US
Priority Data:
62/541,51104.08.2017US
Title (EN) TREATING AND INHIBITING LEUKEMIA WITH NK-92 CELLS
(FR) TRAITEMENT ET INHIBITION DE LA LEUCÉMIE À L'AIDE DE CELLULES NK-92
Abstract:
(EN) Described herein are methods for treating or preventing leukemias with NK-92 cells. In particular, provided are methods of treating or preventing leukemias by administering to a patient one or more doses of NK-92 cells for killing remnant (also referred to as residual) leukemia cells and/or leukemia stem cells. In various embodiments, NK-92 cells are administered to a patient to treat and/or prevent leukemia that is refractory or resistant, or has relapsed in a patient who is recovering from treatment for leukemia under conventional therapies.
(FR) L'invention concerne des procédés de traitement ou de prévention de leucémies à l'aide de cellules NK-92. L'invention concerne en particulier des procédés de traitement ou de prévention de leucémies par administration à un patient d'une ou plusieurs doses de cellules NK-92 pour tuer des restes de cellules leucémiques et/ou cellules souches leucémiques (également appelées résidus). Selon divers modes de réalisation, les cellules NK-92 sont administrées à un patient pour traiter et/ou prévenir la leucémie qui est réfractaire ou résistante, ou qui a récidivé chez un patient qui s'est rétabli à partir d'un traitement pour la leucémie selon des thérapies classiques.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)